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Pathological inflammation and autoimmune disease frequently involves elevated 
neutrophil activity in the absence of infectious agents. Tumour necrosis factor-alpha 
(TNF-) contributes to many of the problems associated with autoimmune diseases. 
In this study we investigated the ability of serum alpha-1 antitrypsin (AAT) to control 
TNF- biosynthesis and signaling in neutrophils and assessed whether AAT 
deficiency (AATD) is a TNF- related disease. In vitro studies demonstrate that 
serum AAT coordinates TNF- intracellular signaling and neutrophil degranulation of 
tertiary and secondary granules via modulation of ligand-receptor interactions. AATD 
patients homozygous for the Z-allele were characterised by increased activation of the 
TNF- system, as demonstrated by increased membrane TNF- levels and increased 
plasma concentrations of TNF receptor 1 (TNF R1) and neutrophil released secondary 
and tertiary granule proteins. The incidence of autoantibodies directed against 
degranulated lactoferrin, and surface protein accessible to these antibodies was 
increased in ZZ-AATD, leading to an enhanced rate of neutrophil reactive oxygen 
species production.  Treatment of ZZ-AATD individuals with AAT augmentation 
therapy results in decreased membrane TNF-expression and plasma levels of 
granule antigenic proteins and IgG-class autoantibodies. These results provide a 
mechanism by which AAT augmentation therapy impacts on TNF- signaling in the 
circulating neutrophil, indicating promising potential of this therapy for other TNF- 






Alpha-1 antitrypsin deficiency (AATD) is a hereditary disorder characterised by low 
circulating levels of the key antiprotease alpha-1 antitrypsin (AAT). AATD is 
associated with the development of chronic obstructive pulmonary disease (COPD) 
often by the 3rd or 4th decade, liver disease and in rare cases skin panniculitis. The 
most common SERPINA1 mutation associated with AATD is the Z mutation and the 
vast majority of AATD individuals diagnosed with COPD are homozygous for the Z 
allele. Current treatment of lung disease associated with AATD is AAT augmentation 
therapy, whereby patients receive weekly infusions of plasma purified AAT. 
Intravenous administration of AAT has been shown to be safe and well tolerated (1, 
2) and results in increased levels of AAT in bronchoalveolar lavage fluid of 
individuals with AATD (3). Observational studies on the clinical efficiency of AAT 
augmentation therapy include a trend towards a slower rate of FEV1 decline (4) and a 
reduction in the incidence of lung infections (5). The EXACTLE study published in 
2009 demonstrated the efficacy of AAT augmentation therapy in preventing the loss 
of lung tissue as measured by computed tomography scan lung density (6). However, 
despite the observed clinical effects of AAT further proof of the effectiveness and 
mechanism of action of augmentation therapy is required (7).  
The notion of AAT as an anti-inflammatory mediator is gaining acceptance (8-
12). AAT has been shown to possess substantial anti-inflammatory properties 
independent of its antiprotease activity affecting a number of cell types, including 
pancreatic islet -cells (13), B-cells (14), mast cells (15) and macrophages (16, 17) 
and has been implicated in cellular processes as diverse as endothelial cell apoptosis 
(11), neutrophil chemotaxis (18) and fibroblast mediated cytokine expression (19). 
Indeed, it is now accepted that AAT has a number of functions beyond protease 
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inhibition highlighting the use of AAT augmentation therapy for a range of diseases 
other than AATD. In this regard, it was discovered that AAT reduced inflammation in 
pancreatic islet cells which lead to multiple studies investigating the potential role of 
AAT in treatment of diabetes (20-24). Other immune-mediated disease models in 
which the effect of AAT has been explored include arthritis (14, 19), Crohn’s disease 
and acute myocardial infarction (25). AAT has also been evaluated as a human 
immunodeficiency virus type 1 (HIV) antagonist and was shown to prevent viral 
replication (26-28). Moreover, the therapeutic effect of AAT investigated in airway 
diseases, not associated with AATD, includes bronchiectasis/COPD and cystic 
fibrosis (2, 17, 29-31).  
TNF-, a potent pro-inflammatory cytokine that operates at an early stage in 
COPD (32, 33) and in other chronic illnesses including cystic fibrosis (34, 35) and 
asthma (36), may also contribute in the development of disease associated with 
AATD. Studies supporting this hypothesis have demonstrated a reduction in TNF- 
levels by AAT in a murine model of emphysema (37) and a positive correlation 
between AAT inactivation and TNF- concentrations has been established in patients 
with rheumatoid arthritis (RA) (38) and cystic fibrosis (39). The consequence of 
elevated levels of TNF- is evident as TNF- blockade has transformed treatment of 
several autoimmune diseases including RA, psoriasis, ankylosing spondylitis and 
inflammatory bowel disease (40). Several small studies have suggested that carriage 
of the Z-allele in AATD is associated with development of autoimmunity and 
antineutrophil cytoplasmic antibodies (ANCA) (41, 42), causing aberrant neutrophil 
activation and ANCA-associated vasculitis (43). Therefore, with the aim of clarifying 
the role of TNF- in AATD related disease, we investigated the impact of AATD on 
TNF- neutrophil activation. This study has identified a pathogenic mechanism 
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associated with AATD and illustrates the anti-inflammatory efficiency of AAT 





















Elevated plasma TNF- and neutrophil secondary and tertiary granule proteins 
in ZZ-AATD. 
To determine the role of TNF- and its potential effect on neutrophil function in vivo, 
cells and plasma samples were obtained from healthy controls (N=10, MM) and non-
obstructed ZZ-AATD patients (N=10, Table 1). Quantification of TNF- by ELISA 
revealed that ZZ-AATD neutrophils cultured for 6 h produced four times more 
soluble TNF- than that measured in supernatants of MM cells (36.86 ± 7.75pg/ml  
and 9.10 ± 5.44pg/ml respectively, P=0.03) (Fig. 1A). Analysis of TNF- plasma 
levels however revealed no significant difference between MM controls and non-
obstructed ZZ-AATD patients (3.5 ± 0.26 pg/ml and 3.9 ± 0.43 pg/ml, respectively, 
P=0.4) (Fig. 1B). This disparity between in vitro and in vivo findings can be explained 
by the that TNF- is not readily detected in biological samples (44), possess a 
relatively short half-life (45) and is rapidly excreted from the body (46). Thus, to 
further evaluate TNF- levels in vivo, flow cytometry analysis of the relative mean 
fluorescence intensity (MFI) of TNF- on the membrane of peripheral blood 
neutrophils was performed (Fig. 1C). Results revealed that ZZ-AATD cells had a 1.5-
fold increased membrane expression of TNF- when compared to MM 
neutrophils1.59 ± 0.19 and 1.07 ± 0.06 MFI respectively, P=0.04). Moreover, it has 
previously been shown that soluble plasma TNF R1 concentrations can act as a 
surrogate marker for TNF-levels (47-49). Thus quantification of TNF R1 levels in 
control and patient plasma was performed (Fig. 1D), with results revealing 36% less 
TNF R1 in healthy control MM plasma when compared to ZZ-AATD patient samples 
(580.6 ± 41.93 pg/ml and 906.9 ± 75.43 pg/ml respectively, P=0.0008).  
 7 
As neutrophil exposure to TNF- has been shown to cause degranulation of 
tertiary and secondary but not primary granules (50), levels of specific components of 
the tertiary and secondary granules were quantified in plasma samples. Matrix 
metalloproteinase 9 (MMP-9) a marker of tertiary granule release was statistically 
higher in non-obstructed ZZ-AATD plasma compared to control MM samples 
(P=0.0002) (Fig. 1E). Moreover, results indicated significantly increased 
degranulation of secondary granules by AATD neutrophils in vivo, as  a 3- and 1.8-
fold increase was observed in levels of human cathelicidin antimicrobial protein 18 
(hCAP-18) (Fig. 1F) and lactoferrin (Fig. 1G) in ZZ-AATD plasma compared to 
control samples (P=0.02 and P=0.03, respectively). Overall these results demonstrate 
that TNF-induced inflammation plays a central role in ZZ-AATD and impacts upon 
neutrophil degranulation processes. 
 
Dysregulated degranulation pattern of neutrophils from ZZ-AATD patients. 
As greater levels of tertiary and secondary granule components were detected in 
plasma of non-obstructed ZZ-AATD patients, a comparison of the rate of neutrophil 
degranulation between MM control donors and individuals with the ZZ phenotype 
was performed. Results demonstrated that unstimulated ZZ-AATD neutrophils 
released a significantly higher level of granule proteins (Fig. 2A-2C). In comparison 
to the MM cell, at the 5 min time point the ZZ neutrophil released a 2-, 8- and 9-fold 
increase in the level of MMP-9, hCAP-18 and lactoferrin, respectively. After a longer 
period of incubation (20 min) there was a 2-, 2.5- and 3-fold increase in the level of 
secreted MMP-9, hCAP-18 and lactoferrin respectively, by ZZ-AATD neutrophils 
compared to MM cells (P=0.04, P=0.03 and P=0.02, respectively) (Fig. 2A-2C).   
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Results also revealed that ZZ-AATD neutrophils exhibited an increased 
degranulation response to TNF- 10ng/2x107/ml) compared to control cells (Fig. 2D-
2F). A significant difference was observed at all individual time points measured from 
5 min onwards, with at least a 2-fold increase in ZZ-AATD neutrophil degranulation 
of MMP-9, hCAP-18 and lactoferrin compared to MM cells after 20 min (Fig. 2D-F; 
P=0.03, P=0.01 and P=0.02 respectively). Control experiments confirmed that freshly 
isolated MM and ZZ-AATD cells contained similar levels of MMP-9, hCAP-18 and 
lactoferrin (fig. S1) and that the concentration of TNF- employed in degranulation 
experiments for 20 min did not induce apoptosis or cell death as verified by annexin 
V and propidium iodide staining of neutrophils (fig. S2). Collectively, these results 
demonstrate that ZZ-AATD neutrophils release increased levels of secondary and 
tertiary granules both under unstimulated and TNF- stimulated conditions, possibly 
indicating that the circulating ZZ-AATD cell is in a primed state.   
 
AAT activity regulates TNF- induced neutrophil degranulation. 
To investigate whether the observed increased exocytosis of tertiary and secondary 
granules by ZZ-AATD neutrophils was a result of low AAT levels, the effect of 
exogenous AAT employed at physiological levels (27.5M) on TNF- induced MM 
and ZZ AATD neutrophil degranulation was examined (Fig. 3). As illustrated in Fig. 
3A, C and E, the increased degranulation of MMP-9, hCAP-18 and lactoferrin 
induced by TNF- in MM cells was significantly inhibited by AAT, with a 2-fold 
decrease observed for all proteins at the 20 min time point (P=0.04, P=0.03 and 
P=0.04, respectively). The effect of a second serum derived serpin, antithrombin III, 
on TNF- induced neutrophil degranulation was also examined.  After 20 min, a 
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physiological concentration of antithrombin III (4M) was shown to have no effect on 
TNF- induced degranulation by MM cells (Fig. 3A, 3C and 3E).   
The inhibitory effect of AAT on TNF- induced degranulation was also 
examined on neutrophils from non-obstructed ZZ-AATD individuals (Fig. 3B, 3D and 
3F). The results demonstrated that after 20 min, there was a trend for reduced levels 
of MMP-9, hCAP-18 and lactoferrin release by ZZ-AATD cells in response to TNF- 
in the presence of physiological levels of AAT when compared to TNF- alone, 
although this reduction did not reach significance. Evaluation of the impact of AAT 
on TNF- signaling and its ability to stimulate MAP kinase p38 phosphorylation, a 
key step in the neutrophil degranulation process (51),  revealed that AAT reduced p38 
phosphorylation in a dose dependent manner with an IC50 of 29.15M (fig. S3). 
Increasing the concentration of AAT to levels observed during inflammation (55-
110M) (52) caused a further decline in p38 phosphorylation (fig. S3A). The study 
also demonstrated an AAT inhibitory dose-response on TNF- induced degranulation 
of MMP-9, hCAP-18 and lactoferrin (fig. S3B, S3C and S3D, respectively). Overall 
this set of experimental results confirms the ability of plasma AAT to regulate TNF- 
induced neutrophil degranulation. 
 
Excessive neutrophil degranulation gives rise to the development of 
autoantibodies in AATD.     
As a consequence of increased neutrophil degranulation and high plasma levels of 
secondary and tertiary granule proteins in ZZ-AATD, the potential for the 
development of autoantibodies in AATD was evaluated.  A comparison of anti-MMP-
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9, anti-hCAP-18 and anti-lactoferrin IgG-class autoantibodies in plasma from patients 
with ZZ-AATD and healthy controls was performed (Table 2, N=30). Overall the 
level of anti-lactoferrin IgG antibodies were significantly higher in the ZZ-AATD 
group when compared to control donors (P=0.001), but there was no significant 
difference in the level of anti-MMP-9 or anti-hCAP-18 IgG autoantibodies (Fig. 4A-
4C). By employing a predetermined threshold level for positivity previously described 
as 3 standard deviations above the mean of MM healthy controls (53), eight of the 30 
ZZ-AATD individuals tested proved positive for autoantibodies against lactoferrin, 
higher than that observed for the other granule proteins (Fig. 4A-4C). Moreover, the 
specificity of plasma purified anti-lactoferrin IgG antibody was confirmed in a 
competitive assay by Western blot analysis (Fig. 4D). Results demonstrated that 
exogenous lactoferrin protein (5g) negatively impacted on the ability of patient 
purified anti-lactoferrin antibody to bind to membrane immobilised lactoferrin, 
resulting in a 5 fold decrease in the signal obtained (P=0.008) (Fig. 4D). Further 
analysis revealed no significant increase in IgM titre against all three granule proteins 
in ZZ-AATD compared to MM control samples, with 1/30, 1/30 and 5/30 patients 
positive for IgM autoantibodies against MMP-9, hCAP-18 and lactoferrin, 
respectively (fig. S4). 
Next, the possibility that autoantibody cross-linking of antigens bound to the 
outer cell surface could trigger signal transduction and neutrophil activation was 
examined. As IgG class autoantibodies directed to lactoferrin of neutrophils were the 
most prevalent in ZZ-AATD, we examined anti-lactoferrin antibody-mediated ROS 
production as a read-out system for cell activation. It was first necessary to confirm 
membrane surface expression of lactoferrin thus enabling interaction between 
antibody and antigen. Western blot analysis of isolated neutrophil plasma membranes 
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demonstrated significantly higher levels of lactoferrin on ZZ-AATD cells compared 
to healthy control samples (P<0.0001) (Fig. 4E). This was further validated by flow 
cytometry analysis of non-permeabilized cells confirming higher expression of 
lactoferrin on the ZZ-AATD neutrophil (1.90 ± 0.26 MFI) when compared to the MM 
cell (1.12 ± 0.11 MFI, P=0.02) (Fig. 4F). Furthermore, incubation of TNF--primed 
MM neutrophils with commercially available anti-lactoferrin IgG resulted in 
superoxide (O2
-
) production similar to TNF--primed cells activated with fMLP, 
albeit at a slower rate (Fig. 4G). Isotype control antibody or TNF- alone had no 
stimulatory effect. In addition, incubation of ZZ-AATD neutrophils with anti-
lactoferrin antibody for 30 min caused a robust increase in extracellular O2
-
 
production, and in comparison MM cells released significantly less (55% lower 
levels, P=0.004) (Fig. 4H).  Whilst additional TNF--priming of ZZ-AATD 
neutrophils in vitro had little effect on the level of O2
-
 produced, TNF--priming of 
MM cells significantly increased O2
-
 production in response to anti-lactoferrin IgG, 
lending further support to the primed state of the ZZ-AATD circulating cell (Fig. 4H). 
In addition, experiments exploring the effect of anti-lactoferrin autoantibodies 
purified from ZZ-AATD plasma revealed that purified anti-lactoferrin autoantibodies 
mediated activation of cells. Incubation of TNF--primed MM neutrophils with 
patient plasma purified anti-lactoferrin autoantibodies resulted in O2
- 
production 
similar to primed cells activated with fMLP (Fig. 4I). From this set of experiments we 
conclude that autoantibodies directed against lactoferrin circulating in the plasma of 
ZZ-AATD patients, can target antigen bound to the cell surface and trigger neutrophil 
ROS production.   
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AAT regulates TNF- signaling by modulating TNF- receptor interaction. 
Results so far have demonstrated the ability of AAT to modulate neutrophil signaling 
in response to exogenous TNF-. In endothelial cells, studies have shown that TNF- 
can regulate its own gene expression (9). Thus in the present study the ability of AAT 
to affect TNF- self-regulated gene and protein expression in the neutrophil like 
human promyelocytic HL-60 cell line was examined.  HL-60 cells (10
7
/ml) were 
incubated with TNF- in the presence or absence of physiological concentrations of 
AAT (27.5M) for 6 h.  Results demonstrated that AAT down-regulated TNF- 
signaling and functioned to significantly reduce TNF- gene expression in HL-60 
cells (P=0.03) (Fig. 5A). The mechanisms of inhibition were shown to involve the 
ability of AAT to prevent TNF- induced activation of NF-B, as demonstrated by 
reduced IκB degradation (Fig. 5B). In support of these results, we observed 
significantly increased NF-B activation in non-obstructed ZZ-AATD neutrophils 
when compared to healthy control cells (Fig. 5C) (P=0.04). Collectively, these results 
indicate that ZZ-AATD neutrophils have increased NF-B activation, further 
suggesting that AATD is associated with a pro-inflammatory phenotype in circulating 
neutrophils.  
Ensuing experiments investigated the possible mechanism by which AAT 
inhibits TNF-induced signaling, degranulation and gene upregulation. The ability of 
AAT to interact with TNF-was examined as previous studies have demonstrated 
that AAT can bind a range of inflammatory mediators (18, 54-56). However, results 
of a Biacore based assay whereby TNF- was coupled to a CM-5 chip demonstrated 
that no binding event occurred between AAT and TNF- (Fig. 5D). As a positive 
control a monoclonal antibody against TNF- was used with a positive binding event 
 13 
of 60 RU detected (Fig. 5D). Ensuing experiments determined whether AAT 
impacted on TNF- binding to its two receptors, TNF R1 and TNF R2. The exposure 
of TNF R1 and TNF R2 coated surfaces to TNF-ngin the presence or absence 
of AAT (27.5M) revealed that AAT significantly reduced TNF- receptor 
engagement. In this regard, AAT significantly reduced TNF- binding to TNF R1 by 
35% (P=0.03) (Fig. 5E), with a similar result observed for TNF R2 (50% reduction; 
P=0.02) (Fig. 5F). As a positive control, a TNF R1 Fc chimera (TNF- blocker) was 
utilised, resulting in a 80% reduction in the level of TNF- binding to TNF R1 and 
R2 (P<0.0001) (Fig. 5E and 5F).  
A previous study has established that AAT can interact with the neutrophil 
through receptors exposed on the membrane surface (18). Thus ensuing experiments 
examined whether AAT may block TNF- receptor engagement by binding TNF R1 
and TNF R2. Polybeads coated with TNF R1, TNF R2 or the IgG receptor FcRIIA 
(the latter acting as a negative control shown previously not to bind to AAT (18)), 
were incubated with AAT followed by a FITC labeled antibody against AAT to 
confirm AAT binding by flow cytometry (Fig. 5G). Results demonstrated a 
significant increase in AAT binding to both TNF R1 (2.44 ± 0.38 MFI) and TNF R2 
(2.43 ± 0.48 MFI) when compared to unlabelled (0.88 ± 0.08 MFI, P=0.01 and 
P=0.04 respectively) or FcRIIA control beads (1.35 ± 0.16 MFI, P=0.03 and P=0.02 
respectively). There was no difference in the level of AAT binding to unlabeled or 
FcRIIA control beads.  
The ability of TNF- to bind to its receptors on the neutrophil membrane in 
vitro in the presence of AAT was next evaluated. By flow cytometry the ability of 
exogenous TNF-ngto bind neutrophil membranes in the absence or presence of 
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AAT (27.5M) was examined utilising an antibody that could detect receptor bound 
TNF-. Results revealed that cells pre-incubated with physiological levels of AAT 
(27.5M) and then exposed to TNF- exhibited a 55% reduction in the level of bound 
TNF- compared to cells exposed to TNF-only (1.20 ± 0.08 MFI and 2.7 ± 0.03 
MFI, respectively, P<0.0001) (Fig. 5H). Collectively, these results indicate that TNF-
 signaling can be regulated by physiological concentrations of AAT and that this 
regulation occurs at the membrane level, negating TNF- receptor interaction.  
 
An evaluation of the effects of long term administration of AAT augmentation 
therapy in ZZ-AATD patients. 
Thus far results have demonstrated the ability of AAT to modulate TNF- signaling 
and the downstream effects on neutrophil function in vitro. Next the impact of AAT 
on TNF- signaling in vivo was examined by investigating the impact of AAT 
augmentation therapy.  Samples were isolated from ZZ-AATD patients possessing an 
FEV1 of 30-70% predicted and who were on augmentation therapy for over 4 years 
(N=3), ZZ-AATD patients who had never received augmentation therapy (N=3, FEV1 
30-70% predicted) and healthy controls. Flow cytometry analysis of AAT on 
neutrophil membranes illustrated a 2-fold increase in ZZ-AATD patients currently 
receiving augmentation therapy when compared to ZZ-AATD patients who have 
never received AAT infusions (1.09 ± 0.18 and 0.56 ± 0.03 MFI respectively, P=0.04) 
(Fig. 6A). Subsequent analysis of membrane TNF- levels revealed that 
augmentation therapy caused a 1.7-fold decrease in TNF-expression on ZZ-AATD 
neutrophil membranes when compared to cells isolated from ZZ-AATD patients who 
had never received AAT treatment (0.95 ± 0.15 and 1.62 ± 0.10 MFI respectively, 
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P=0.01) (Fig. 6B). Moreover, the membrane expression levels of TNF- were similar 
between ZZ-AATD patient cells on augmentation therapy and MM control neutrophil 
membranes (1.00 ± 0.16 MFI) (Fig. 6B). In addition, the level of soluble TNF R1 
detected in plasma samples was decreased by approximately 30% in ZZ-AATD 
patients receiving augmentation therapy when compared to patients not receiving 
treatment (827.4 ± 92.37 pg/ml and 1258 ± 124.9 pg/ml respectively, P=0.03) (Fig. 
6C). The levels recorded in the augmentation therapy group were not statistically 
different when compared to the level of soluble TNF R1 in MM controls. Analysis of 
the soluble TNF R2 receptor levels in plasma revealed no significant difference 
between MM, ZZ-AATD patients receiving AAT augmentation therapy and ZZ-
AATD patient group who had never received AAT infusions (fig. S5). This is in line 
with a previous study indicating that levels of soluble TNF R1, but not TNF R2, are 
elevated in COPD (57). 
Finally, as data from this study has demonstrated the presence of circulating 
levels of autoantibodies against lactoferrin in ZZ-AATD patients (Fig. 4C), we 
evaluated autoantibody titre levels in plasma from ZZ-AATD individuals (N=4) prior 
to starting augmentation therapy and 4 years post treatment. As illustrated in Fig. 6D, 
results demonstrated that the titre of anti-lactoferrin autoantibodies decreased by 30% 
after four years of receiving AAT infusions (P=0.04), thus indicating the benefit of 
long term therapy in suppressing autoimmunity.  
 
The impact of weekly AAT augmentation therapy infusions upon neutrophil 
degranulation.  
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Weekly infusions of AAT augmentation therapy increase the serum levels of AAT in 
AATD patients, but eventually these levels rapidly decline from normal to near or 
below that which is considered the “protective threshold” of 11 M prior to the 
patient’s next infusion (3). This led us to evaluate the impact of the pharmacokinetics 
of weekly AAT augmentation therapy infusions (60mg/kg of patient body weight) on 
TNF- and neutrophil degranulation markers. Plasma and neutrophils were isolated 
from ZZ-AATD patients who were receiving weekly AAT augmentation therapy with 
samples collected on day 2 and day 7 post infusion. The impact of AAT augmentation 
therapy resulted in significantly increased levels of AAT on day 2 compared to day 7 
post treatment (30.2M and 7.59M respectively, P=0.004) (Fig. 7A). Results of flow 
cytometry analysis revealed that ZZ neutrophils illustrated significantly reduced 
levels of membrane associated TNF-on day 2 post treatment (0.77 ± 0.12 MFI) 
when compared to day 7 cells (1.11 ± 0.13 MFI, P=0.0004) (Fig. 7B). To investigate 
whether AAT augmentation therapy corrected the dysregulated degranulation pattern 
of ZZ-AATD neutrophils, the CD66b membrane expression profile of ZZ-AATD 
neutrophils was assessed by flow cytometry analysis (Fig. 7C).  CD66b is a 
membrane receptor that is exclusively present on secondary and tertiary granules (58) 
and upon degranulation becomes expressed on the cell surface. When compared to 
day 2 neutrophils (0.74 ± 0.12 MFI), day 7 cells demonstrated a significant increase in 
CD66b on neutrophil membranes (1.02 ± 0.08 MFI, P=0.03), indicative of increased 
levels of degranulation. This latter result was supported by lower concentrations of 
degranulated secondary and tertiary granule proteins in plasma samples on day 2 
when compared to day 7 post treatment. Zymographic analyses revealed an 
approximate 25% increase in circulating plasma levels of MMP-9 on day 7 post 
treatment when compared to day 2 (P=0.01) (Fig. 7D). Likewise, there was a 
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significant increase in the plasma levels of hCAP-18 and lactoferrin on day 7 post 
augmentation therapy when compared to day 2 post treatment (P=0.03 and P=0.04 
respectively) (Fig. 7E and 7F). Collectively, these results illustrate the effect of 
weekly AAT infusions on TNF- membrane expression and the degranulation 
activity of circulating neutrophils in vivo, both of which are clearly related to the 

















Classically, AAT has been considered an important modulator of lung disease through 
inhibition of serine proteases and restoration of the antiprotease / protease balance in 
the airways (31, 59). More recently however, reports have highlighted anti-
inflammatory attributes of AAT including inhibition of cell apoptosis (60, 61). In the 
present study we demonstrate that AAT plays a direct role in modulating TNF- 
signaling in neutrophils and functions to decrease the degranulation process of 
circulating cells. We have elucidated a role for AAT and uncovered the capacity of 
this serum protein to modulate the degranulation response of TNFR1 and TNFR2 
receptor signaling by interrupting ligand-receptor interaction. In AATD, this 
regulatory mechanism is considerably perturbed and an association between low 
plasma levels of AAT and high levels of exocytosed granule proteins including 
lactoferrin, hCAP-18 and MMP-9 was observed, characteristic of an in vivo hyper-
responsive state of AATD neutrophils. Consequently, patients with AATD can 
potentially develop agonistic autoantibodies against granule proteins including 
lactoferrin, which in turn can cause neutrophil activation and ROS production (Fig. 
8). 
Circulatory levels of soluble TNF R1 have been shown to be elevated in  
inflammatory lung conditions including COPD (62, 63), and TNF R1 is thought to be 
a more reliable marker of activation of the TNF- system due to its high 
concentration and stability (44, 62). Within this study, we observed a significant 
increase in plasma levels of soluble TNF R1 in ZZ-AATD patients compared to MM 
individuals.  Furthermore, a 1.5-fold increase in TNF- membrane expression was 
detected in ZZ-AATD neutrophils when compared to healthy controls, a level similar 
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to that documented on neutrophils of individuals with RA (64). In this study we also 
show that ZZ-AATD neutrophils secrete significantly higher levels of TNF-. These 
results indicated that TNF- could play a key role in the progression of AATD related 
disease and raised the possibility that AAT could modulate TNF-bioactivity. In this 
regard, TNF- is a potent inducer of the release of neutrophil secondary and tertiary 
granules (65). At baseline and also in response to TNF-, neutrophil degranulation 
capacity was significantly higher in ZZ-AATD patients, with elevated levels of 
secondary (hCAP-18 and lactoferrin) and tertiary (MMP-9) granule proteins released 
compared to healthy MM control cells. TNF- does not cause release of primary 
granules (50) and this was further confirmed within this study as only hCAP-18 
precursor protein (18kDa) was detected by Western blotting due to the requirement of 
proteinase-3 for its activation (66), a serine protease component of primary granules. 
The findings of enhanced TNF--induced degranulation by ZZ-AATD neutrophils are 
in keeping with a pivotal role for AAT in modulation of TNF-signaling and in 
support of this theory, physiological concentrations of AAT (27.5M) exhibited 
significant inhibition of degranulation by MM control cells in response to TNF-. 
This inhibition of TNF- signaling was specific to AAT as another serpin member 
and acute phase protein, antithrombin III, had no effect on TNF-induced neutrophil 
degranulation. In line with these results, a previous study by Mansell et al., (2001) 
demonstrated the inability of antithrombin III to regulate TNF- signaling in a 
monocytic cell line (67). Moreover, experiments assessing the effect of AAT on ZZ-
AATD cells revealed that AAT had a lesser inhibitory effect on TNF- induced 
degranulation compared to MM neutrophils. This latter observation is possibly due to 
the primed state of the ZZ-cell, as evident by the increased level of membrane TNF-, 
 20 
which has previously been shown associated with priming (68). Thus, by corollary 
results of our study also indicate that AAT is incapable of de-priming the cell, a 
phenomenon that has been previously documented to occur in neutrophils (69, 70).  
One attribute associated with TNF- signaling is its ability to self-regulate its 
own gene expression (71), as well as the expression of other inflammatory mediators 
through the NFB pathway (72, 73). Similar to the effect observed in endothelial cells 
(9), our in vitro studies found that AAT down regulated TNF- gene expression in 
response to exogenous TNF- and further revealed that AAT caused a blockade of 
IB degradation. Moreover, Western blot analysis of whole cell lysates of isolated 
peripheral blood neutrophils indicated lower levels of IB in ZZ-AATD cells when 
compared to MM controls suggesting elevated NFB activation in AATD. This result 
is comparable to that observed in neutrophils isolated from patients with RA, which at 
baseline exhibited higher NFB activation when compared to the relative control 
group (64).  
The observed excessive neutrophil degranulation by ZZ-AATD cells prompted 
us to question the consequence and possible impact on disease progression. A number 
of studies have indicated that the Z allele is increased in ANCA-associated vasculitis, 
with 5-27% of individuals with granulomatosis with polyangiitis carrying the Z allele 
(74-77). Based on the fact that lactoferrin is a highly abundant neutrophil protein (78, 
79) and also as elevated levels of this iron-binding protein were detected in ZZ-
AATD plasma, we evaluated an association with the development of autoantibodies. 
Results revealed that of 30 ZZ-AATD patients, 27 % were positive for anti-lactoferrin 
IgG while only 17 % were positive for anti-lactoferrin IgM antibodies. Lactoferrin-
autoantibody positivity has previously been associated with disease activity in RA 
 21 
(80), ankylosing spondylitis (81), systemic lupus erythematosus (82) and 
inflammatory bowel diseases (83), with a higher positivity for IgG autoantibodies 
against lactoferrin detected compared to IgM (82).  
Nevertheless, one requirement for an effective autoantibody that plays a role 
in disease progression is the presence of the antigen on the cell membrane surface 
(84). To this end, we recorded an increase in lactoferrin on the outer surface of the 
ZZ-AATD neutrophil plasma membrane. In turn, the AATD cell was highly receptive 
to anti-lactoferrin antibody exposure, resulting in increased ROS production as 
measured by superoxide anion release. Simultaneous incubation of MM neutrophils 
with priming levels of TNF- and purified anti-lactoferrin antibody was required to 
reach ROS levels similar to ZZ cells exposed to anti-lactoferrin antibody only.  
To support in vitro results demonstrating the ability of AAT to modulate TNF-
 signaling, we isolated plasma and neutrophils from ZZ-AATD patients who had 
been receiving AAT augmentation therapy for more than 4 years and a matched ZZ-
AATD patient group who had never received AAT infusions. Results revealed that 
augmentation therapy significantly increased neutrophil membrane levels of AAT and 
decreased TNF- surface membrane expression in neutrophils from patients receiving 
augmentation therapy, with the level of reduction (1.5 fold) observed similar to that 
recorded post-anti-TNF- therapy in patients with RA (64). As plasma TNF- has a 
short half-life (44-46), the evaluation of other surrogate plasma markers, such as 
soluble TNF R1 (47-49) was employed. Results confirmed reduced levels of TNF R1 
only in patients receiving augmentation therapy when compared to patients not 
receiving treatment, thereby demonstrating that infused AAT modulates activation of 
the TNF- system.  In contrast however, a previous study reported no significant 
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difference between serum levels of TNF-of patients receiving therapy compared to 
patients not receiving AAT augmentation treatment (85). Thus the results of the 
present study highlight the drawback of examining only serum or plasma levels of 
TNF-.  In addition, our results confirm the long-term efficacy of AAT augmentation 
therapy, as individuals receiving therapy for 4 years illustrated a significant decrease 
in titre of autoantibodies directed against lactoferrin.  
 The results of the present study analysing the effect of weekly infusions on 
TNF- and neutrophil biology have identified a possible drawback of the current 
practice of weekly AAT infusions (60mg per kilo) to AATD patients. It has been 
established that weekly infusions of AAT augmentation therapy results in a peak and 
trough effect with regards to the AAT levels, resulting in initially normal to high 
levels of AAT in the circulation for several days after infusion. After this, however, 
the levels of AAT fall to near or below the protective threshold (3). The present study 
demonstrates that during the trough phase of augmentation therapy (day 7, AAT level 
of 7.59M), neutrophils are in a primed state, as demonstrated by elevated TNF- 
membrane levels and increased plasma concentrations of neutrophil degranulation 
markers. This part of the study specifically highlights the need for further studies 
evaluating dosing strategies in AAT augmentation therapy in order to maintain daily 
raised levels of AAT throughout treatment. 
A number of limitations to this study should be discussed. Firstly, the absence 
of data evaluating the consequence of mid-level AAT plasma levels, as observed in 
MZ and SZ AATD phenotypes, on neutrophil function has not been addressed. This is 
an area of importance considering the high number of individuals whom are 
heterozygous for AATD (86, 87). Indeed, previous studies have indicated that 
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individuals with heterozygous AAT deficiency have an increased risk of developing 
lung disease when compared to healthy MM controls (88, 89). In addition, due to the 
recruitment criteria a second limitation of this study is the participation of a relatively 
small number of AATD patients receiving augmentation therapy. Despite this 
drawback however, the data provides evidence of the impact of infused AAT on TNF-
 signaling in the circulating neutrophil.  
In summary, our study has identified TNF- as a potential parameter of 
disease progression and through the setting of AATD we have identified AAT as a 
natural modulator of TNF-signaling. These results highlight the important role that 
AAT plays in regulating neutrophil biology and the possibility of AAT therapy as an 












Materials and methods 
Study Design 
Ethical approval from Beaumont Hospital Institutional Review Board was acquired 
and written informed consent obtained from all study participants. Control volunteers 
(Table 1; N=10 subjects, mean age 28.3  7.2; Table 2; N=30 subjects, mean age 35.2 
2.2) showed no evidence of any disease and had no respiratory symptoms; none 
were taking medication, all non-smokers and all proven MM phenotype with serum 
AAT concentrations within the normal range (25-50M). ZZ-AATD patients were 
recruited from the Irish Alpha-1 Antitrypsin Deficiency Registry and were classified 
into three groups as follows: 
1: Non-obstructed ZZ-AATD individuals, not receiving augmentation therapy (N=10 
subjects, mean age 31.8  16.5). Patients were clinically stable, non-smokers, with no 
evidence of exacerbations in the previous six months. Forced expiratory volume in 
one second (FEV1) was 108.4  13.6% predicted (Table 1).  
2: Non-smoking ZZ-AATD patients who were not receiving augmentation therapy 
(N=30 subjects) with a FEV1 of 74.7 ± 6.3% predicted (Table 2).  
3: ZZ-AATD patients (non-smokers, N=4 subjects, mean age 56.5 ± 2.7, FEV1 
52.25% ± 8.27% predicted) on augmentation therapy who were receiving plasma 
purified AAT from CSL Behring (Zemaira
®
), given intravenously at a dosage of 
60mg/kg body weight weekly for 4 years. In the four weeks prior to obtaining blood 
samples, all patients were exacerbation free.  
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Chemicals and reagents 
All chemicals and reagents used in this study were of the highest purity available, 
endotoxin free and were purchased from Sigma Aldrich unless otherwise indicated.  
Plasma isolation 
Blood was collected in Sarstedt Monovette tubes containing lithium-heparin. Plasma 
was immediately isolated by centrifugation of the blood (1000 x g, 10 min at room 
temperature) which was then aliquoted and stored at -80
o
C until required. 
Purification and lysis of human neutrophils  
Neutrophils were isolated from healthy control and ZZ-AATD whole blood by 
dextran sedimentation and Lymphoprep (Axis-Shield PoC) centrifugation as 
previously described (90). Purified cells were re-suspended in phosphate-buffered 
saline (PBS) (pH 7.4) containing 5mM glucose (PBSG) and used immediately. Purity 
of isolated neutrophils was validated by flow cytometry analysis using a monoclonal 
antibody against CD16b, a specific neutrophil marker (91). Neutrophil viability was 
assessed by trypan blue exclusion assay. Results confirmed viability of neutrophils 
above 98% and the purity of isolated neutrophils was greater than 96%.  
Neutrophil plasma membranes were isolated by sucrose gradient subcellular 
fractionation as previously described (18). Whole cell lysates for Western blot 
analysis were prepared from neutrophils (10
7
/ml) using radio immunoprecipitation 
assay (RIPA) buffer (10mM Tris, pH 7.4, 100mM NaCl, 1mM EDTA, 1mM EGTA, 
1mM NaF, 20mM Na4P2O7, 2mM Na3VO4, 1% Triton X-100, 10% glycerol, 0.1% 
SDS, and 0.5% deoxycholate)  containing protease inhibitors (13M aprotinin, 5mM 
benzamidine, 0.15mM Nα-Tosyl-L-lysine chloromethyl ketone hydrochloride 
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(TLCK), 0.5mM N-p-Tosyl-L-phenylalanine chloromethyl ketone (TPCK), 20mM N-
(Methoxysuccinyl)-Ala-Ala-Pro-Val-chloromethyl ketone (MeOSuc-AAPV-CMK), 
10M soybean trypsin inhibitor (SBTI), orthophenanthroline and 0.2M pefabloc) and 
phosphatase inhibitors (2mM sodium orthovanadate and 2mM sodium 
pyrophosphate).  
Quantification of TNF-, soluble TNF R1, lactoferrin, hCAP-18, MMP-9 and 
AAT in plasma 
For the quantification of TNF- plasma levels, the Human TNF-alpha Ultra-Sensitive 
Kit (Cat Number K151BHC-1) was employed according to the manufacturer’s 
instructions (Meso Scale Discovery). Analysis of soluble TNF R1 (R&D Systems), 
lactoferrin and hCAP-18 was by sandwich ELISA (the latter two from Cambridge 
Bioscience). MMP-9 was quantified in plasma samples by zymography using novex 
gelatin zymogram gels (Invitrogen) according to the manufacturer’s instructions. The 
MMP-9 (85kDa) band was visualised and quantified by densitometry using the 
Syngene G:BOX Chemi XL gel documentation system (92). AAT levels in plasma 
were determined by immune turbidimetry (Olympus AU5400). 
Neutrophil degranulation assay  
Purified neutrophils from healthy controls and/or non-obstructed ZZ-AATD patients 
were re-suspended in PBSG (2x10
7
/ml). Cells were either unstimulated or stimulated 
with TNF- (10ng) at 37oC in the presence or absence of increasing AAT 
concentrations (6.1, 13.25, 27.5, 55 or 110M; Athens Research & Technology) for 0, 
5, 10 or 20 min. Cell free supernatants were harvested following centrifugation at 500 
x g for 5 min at 4
o
C and analysed for degranulated proteins by Western blotting. As a 
control the use of equal cell numbers (2x10
7
/ml) in each reaction was demonstrated 
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by identical Coomassie blue stained electrophoretic profiles of whole cell lysates 
prepared form cells employed in each reaction (fig. S6 & S7).  
SDS-PAGE and Western blot analysis  
SDS-PAGE analyses of samples were carried out under denaturing conditions. 
Samples were electrophoresed using 12% NuPAGE® gels (Invitrogen) according to 
the manufacturer’s instructions. After electrophoresis, gels were stained by 
Coomassie Blue R250 for visualization of proteins or alternatively proteins were 
transferred onto 0.2μm nitrocellulose or PVDF membrane by Western blotting using a 
semi dry blotter for 1 h at 100 mA. Efficient transfer was verified by Ponceau S 
staining of membrane followed by blocking the membrane in PBS-tween containing 
3% (w/v) non-fat dried milk and 1% (w/v) bovine serum albumin (BSA). The 
following primary antibodies were utilized at a concentration of 1g/ml; polyclonal 
goat anti-MMP-9 (R&D Systems); polyclonal rabbit anti-hCAP-18 (Invitrogen); 
polyclonal rabbit anti-lactoferrin; polyclonal rabbit anti-IB; polyclonal rabbit anti-
GAPDH; monoclonal mouse anti-p38 MAPK (all from Santa Cruz Biotechnology), 
monoclonal anti-actin antibody (Millipore) and polyclonal rabbit anti-phopsho-p38 
MAPK (both from Cell Signaling Technology).  Relative secondary antibodies were 
all horseradish peroxidase (HRP) linked anti-goat, rabbit or mouse (Cell Signaling 
Technology). Immunoreactive bands were visualized by utilising chemiluminescent 
HRP substrate (Millipore). Images and densitometry were obtained on the Syngene 
G:BOX Chemi XL gel documentation system. 
Cell culturing 
The HL-60 neutrophil like cell line (ATCC-CCL-240), were grown in complete RPMI 
media containing 10% (v/v) heat-inactivated fetal calf serum (FCS) and 1% (v/v) 
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penicillin/streptomycin in a humidified incubator at 37°C with 5% CO2 until the 
required cell density was obtained. Cells (10
7
/ml) were washed in RPMI with no 
added FCS and resuspended in RPMI and either left untreated (control) or treated 
with TNF- (2ng) in the presence or absence of physiological concentrations of AAT 
(27.5μM). NFB activation was assessed by Western blot analysis of IB 
degradation in whole cell lysates of HL-60s (10
7
/ml) using RIPA Buffer. To quantify 
basal release of TNF- by MM and ZZ-AATD cells, neutrophils were cultured for 6 h 
as previously described (18) with cell free supernatants analysed for TNF- levels by 
ELISA (R&D Systems) employing the manufacturer’s instructions.  
Real time RT-PCR 
TNF- gene expression was assessed by real time RT-PCR as previously described 
(93), using SYBR Green I Master mix (Roche) with the LightCycler 480 PCR system 
(Roche). Primers for TNF- (94) and GAPDH (95) were as previously described and 
obtained from MWG Biotech. PCR was performed using the following protocol: 
preincubation (95°C for 3 min); amplification [50 cycles consisting of denaturation, 
annealing, elongation (10 sec at 95°C; 10 sec at 57°C for both TNF-α and GAPDH; 
and 72°C for 10 sec); melting curve analysis (95°C for 5 sec, 65°C for 1 min, and 
97°C for 5 continuous acquisitions)]; and final cooling step to 4°C. All PCRs were 
carried out in 96-well plates in 20μl reaction volumes and a negative control without 
cDNA was included in every run. The expression of target genes relative to GAPDH 
was determined using the 2
-C
T method (96). 
Flow cytometry analysis  
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Isolated neutrophils were fixed with 4% (w/v) paraformaldehyde for 10 min. Cells 
were then washed and blocked with 2% (w/v) BSA, followed by incubation with 
primary detection antibodies at a concentration of 1g/106 cells for 30 min. Primary 
antibodies consisted of mouse monoclonal anti-CD16b (Santa Cruz Biotechnology), 
monoclonal anti-TNF-FITC (R&D Systems); mouse monoclonal anti-CD66b FITC 
(BD Biosciences), rabbit polyclonal anti-lactoferrin (Santa Cruz Biotechnology) and 
goat polyclonal anti-AAT FITC (Abcam). Control samples were exposed to relevant 
non-specific isotype control antibodies (goat IgG, rabbit IgG, mouse IgG1 or IgM; all 
from Santa Cruz Biotechnology) or secondary FITC labeled antibodies alone (FITC 
goat anti-rabbit (Abcam) or FITC goat anti-mouse IgG (Santa Cruz Biotechnology)) 
(fig. S8).  
In a subset of experiments, flow cytometry was employed to evaluate the 
ability of exogenous TNF- to bind neutrophils as previously described (97).  In brief, 
neutrophils were incubated with or without TNF- (10ng) in the presence or absence 
of AAT (27.5M). After 10 min, cells were washed and then fixed and blocked as 
already described. TNF- binding was quantified by incubating cells with a FITC 
labeled monoclonal antibody that can detect receptor bound TNF- (R&D systems, 
2g/106 cells) (fig. S9). Cells were washed in PBS and fluorescence counted using a 
BD FACSCalibur (Becton, Dikenson). Ten thousand events per reaction was 
quantified.  Analysis of apoptosis and dead cells following TNF- treatment was 
evaluated by using an Annexin V-FITC Apoptosis Kit (BioVision).   
In vitro protein binding assays 
Analysis of the binding interaction of TNF- with AAT was carried out using a 
surface-plasmon resonance assay for real-time and label-free detection.  A positive 
 30 
protein:protein interaction results in an increase in response units (RU). This was 
performed on a Biacore 2000 instrument using a CM-5 carboxymethylated dextran 
sensor chip (GE Healthcare) In brief; TNF- (500ng/ml) was immobilized onto a 
CM-5 chip. Interaction between bound TNF- and a mouse monoclonal anti-TNF- 
antibody (R&D systems, 50nM; positive control) or AAT (5M) was performed. All 
analyses were carried out in triplicate on 3 independent days, and binding responses 
(response unit [RU]) were monitored. 
TNF- and TNF receptor binding assays were carried out as previously 
described (18). Briefly, recombinant TNF receptor (TNFR1 or TNFR2; AbD Serotec) 
coated 96 well immunlon plates were exposed to TNF- (10ng) in the presence or 
absence of AAT (27.5M) or a TNF R1 Fc chimera (5nM) (TNF- blocker, R&D 
Systems). A monoclonal anti-TNF- antibody (R&D Systems) followed by HRP 
labeled rabbit anti mouse HRP antibody was utilised to detect a TNF- binding event. 
Peroxidase activity was quantified by ABTS substrate and the resulting absorbance 
measured at 405nm.  
A bead based assay was used to examine AAT and TNF receptor interaction 
as previously described (98). In brief, Polybeads (Polysicence Inc) were coated with 
either TNF R1 or TNF R2 (200nM) (R&D Systems) in Voller’s buffer (15mM 
Na2CO3 and 35mM NaHCO3, pH 9.3). As negative controls, beads were either 
unlabeled or coated with FcRIIA (200nM) (R&D Systems) as AAT has previously 
been shown not to bind to this receptor (18). AAT (27.5M) was incubated with the 
beads for 30 min at room temperature. Beads were washed and blocked with 2% 
(w/v) BSA in PBS. To confirm AAT interaction, flow cytometry was utilised by 
employing a FITC labeled polyclonal goat antibody against AAT (Abcam, 1g/106 
 31 
beads).  Relative isotype control antibody (FITC labelled goat IgG) was employed as 
a negative control.  
Auto-antibody quantification and purification  
An ELISA based method was utilised for the evaluation of autoantibodies against key 
secondary and tertiary granule proteins as previously described (53). In brief, purified 
lactoferrin, MMP-9 and hCAP-18 (10g/ml) coated ELISA plates were incubated 
with plasma samples from MM healthy controls (N=30) and ZZ-AATD patients 
(N=30) (Table 2). The plates were washed and then incubated with a secondary rabbit 
anti-human IgG HRP or goat anti-human IgM HRP detection antibody (Sigma 
Aldrich) as per manufacturer’s instructions. Peroxidase substrate ABTS was 
employed to determine positive signals within the assay. Three standard deviations of 
the healthy control group was used a positive cut off point (53). Anti lactoferrin 
antibody from ZZ-AATD plasma was purified as previously described (99).  The 
specificity of the purified antibody was confirmed by Western blot analysis. Purified 
human lactoferrin (1g per lane) was electrophoresed and transferred to PVDF 
membrane. The purified anti-lactoferrin antibody was utilised as a primary antibody 
in the absence or presence of exogenous lactoferrin protein (5g). Rabbit anti-human 
IgG HRP antibody was utilised as a detection antibody. Western blot signals were 
quantified by densitometry as described above.  
Cytochrome C reduction assay 
A cytochrome C reduction assay was employed to measure production of superoxide 
(O2
-
) by neutrophils as previously described (18). In brief, cells (5x10
5
/200l) in 
cytochrome C buffer (100nM cytochrome C, 2mM MgCl2, 2mM CaCl2, 5mM glucose 
in PBS) were either untreated or treated with TNF- as a priming agent (10ng) 
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followed by exposure to either rabbit anti-lactoferrin IgG antibody (1g), the bacterial 
peptide fMLP (10
-6
M) or purified human anti-lactoferrin (300ng). The reduction of 
cytochrome was recorded at 550nm over 60 min.  
Statistical analysis  
Results are expressed as means ± standard error of the mean (SEM) of biological 
replicates or independent experiments as stated in the figure legends. The data were 
analyzed with GraphPad Prism version 4.03 for Windows. Where appropriate a 
comparison of categorical data distributions by the D’Agostino–Pearson omnibus 
methods to test continuous data for normality of distribution was performed. The 
groups were compared by Student’s t-test when normally distributed or by the 
nonparametric Mann–Whitney U test. Statistical comparisons of small data sets 















Fig. S1. Equal tertiary and secondary granule protein expression in MM and ZZ-
AATD neutrophils 
Fig. S2. TNF- exposure for 20 min does not induce apoptosis in MM or ZZ-AATD 
neutrophils  
Fig. S3.  Physiological and acute phase levels of AAT modulates TNF- induced 
degranulation  
Fig. S4. IgM autoantibodies against granule proteins in ZZ-AATD. 
Fig. S5. Augmentation therapy does not impact upon soluble plasma levels of TNF 
R2.  
Fig S6. Loading controls for Western blots analysing healthy control (MM) and ZZ-
AATD neutrophil degranulation.  
Fig. S7. Loading controls for Western blots analysing the effect of AAT compared to 
antithrombin III on neutrophil degranulation.  
Fig. S8. Isotype controls for flow cytometry analysis of MM and ZZ-AATD 
neutrophils for TNF-, lactoferrin, AAT and CD66b 
Fig. S9. Isotype control for flow cytometry analysis of the ability of AAT to modulate 
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Table 1. Characteristics of healthy controls and non-obstructed ZZ-AATD 





   
No. of subjects 10 10 
Gender,  male/female 4/6 6/4 
Age, years  (Mean  SD) 31.816.5 28.37.2 
FEV1, % predicted  108.413.6 100.610.9 
FVC, % predicted 114.919.9 105.716.6 
FEV1/FVC % 80.64.1 827.1 
DLCO % predicted 85.711.7 - 
BMI 24.857.0 26.94.8 
Bronchiectasis on HRCT 2/10 - 
Definition of abbreviations: SD = Standard deviation, FEV1 = Forced expiratory 
volume in one second, FVC = Forced vital capacity, DLCO = Diffusion capacity for 















Table 2. Characteristics of healthy control (MM) and ZZ-AATD patients 





   
No. of subjects 30 30 
Gender,  male/female 14/16 16/14 
Age, years  (Mean  SD) 35.22.2 47.52.9 
FEV1, % predicted  99.85.8 74.76.3 
Definition of abbreviations: SD = Standard deviation, FEV1 = Forced expiratory 





















Fig. 1. TNF- and neutrophil secondary and tertiary granule proteins in ZZ-
AATD.  
(A) TNF- in cell supernatants from cultured peripheral blood neutrophils isolated 
from healthy control donors (MM) and ZZ-AATD patients (ZZ) was quantified by 
ELISA . Levels were significantly elevated in ZZ-AATD compared to the MM control 
group (P=0.03, N=5 subjects per group, Student’s t-test). (B) No significant difference 
was observed in plasma levels of TNF-between ZZ-AATD patients and MM healthy 
controls (P=0.4, N=10 subjects per group, Student’s t-test). (C) Analysis of TNF- 
revealed a significant increase in membrane expression on ZZ-AATD neutrophils 
when compared to control MM cells (P=0.04, N=3 subjects per group, Student’s t-
test). (D) Levels of soluble TNF R1 were significantly higher in ZZ-AATD plasma 
samples when compared to MM controls (P=0.0008, N=10 subjects per group, 
Student’s t-test). (E) Levels of MMP-9 were quantified by zymography and expressed 
as relative densitometry units (DU; P=0.0002, N=10 subjects per group, Student’s t-
test)), (F) hCAP-18 (P=0.02, N=10 subjects per group, Mann-Whitney U test) and 
(G) lactoferrin (P=0.03, N=10 subjects per group, Student’s t-test) quantified by 
ELISA and expressed as ng/ml, were significantly higher in plasma of ZZ-AATD 
individuals compared to MM healthy donors. All measurements are mean ± SEM 















Fig. 2. Increased degranulation of secondary and tertiary granules by ZZ-AATD 
neutrophils in response to TNF-   
Neutrophils isolated from MM (□) or ZZ-AATD (■) individuals were incubated at 
37
o
C and were either unstimulated (A-C) or treated with TNF- (D-F).  Cell free 
supernatants were collected at 0, 5, 10 or 20 min and Western blotted for markers of 
tertiary granule [MMP-9 (A&D)] or secondary granule [hCAP-18 (B&E) and 
lactoferrin (C&F)] release. ZZ-AATD neutrophils released significantly greater levels 
of both granule types when compared to MM cells (P<0.05, N=3 subjects per group, 
Student’s t-test). All results (expressed as relative densitometry units) are 
representative of three independent experiments. All measurements are mean ± SEM 









Fig. 3. AAT modulates TNF- induced neutrophil degranulation. 
Neutrophils were isolated from MM healthy controls (A, C & E) and asymptomatic 
ZZ-AATD patients (B, D & F). Cells were either unstimulated (Con) or stimulated 
with TNF- in the absence or presence of either AAT (27.5M) or antithrombin III 
(AThr III, 4M). Supernatants were analysed by Western blotting to determine 
neutrophil degranulation. AAT significantly reduced degranulation of MMP-9 (A), 
hCAP-18 (C) and lactoferrin (E) by MM neutrophils stimulated with TNF-after 20 
min, while AThr III had no effect (P<0.05 between TNF- and TNF- with AAT at 
the respective time points, N=3 subjects per group, Student’s t-test). Physiological 
levels of AAT (27.5M) had no significant impact on TNF- induce degranulation of 
MMP-9 (B), hCAP-18 (D) and lactoferrin (F) from asymptomatic ZZ-AATD 
neutrophils. All results are expressed as relative densitometry units. All measurements 





Fig. 4. Autoantibodies in ZZ-AATD are associated with increased neutrophil 
activation and ROS production. 
IgG autoantibodies against MMP-9 (A), hCAP-18 (B) and lactoferrin (C) were 
quantified in plasma of MM healthy controls and ZZ-AATD individuals. A significant 
increase in the titre of lactoferrin autoantibodies were detected in ZZ-AATD patients 
(P=0.001, N=30 subjects per group, Mann-Whitney U test). Positivity was set as 3 
standard deviations above the mean of MM healthy controls as indicated by the 
hatched line. 1, 2 and 8 of 30 ZZ-AATD samples were positive for MMP-9, hCAP-18 
and lactoferrin autoantibodies, respectively. (D) The specificity of purified anti-
lactoferrin antibody from patient’s sera was evaluated by Western blot analysis. The 
presence of exogenous lactoferrin (Lf) significantly reduced the ability of the purified 
human anti-lactoferrin to detect PVDF membrane immobilised lactoferrin (P<0.0001, 
N=3 independent experiments, Student’s t-test). By Western blot (employing -actin 
as a loading control) (E) and flow cytometry analysis (F), significantly increased 
levels of degranulated lactoferrin (Lf) were found bound to the outer surface of ZZ-
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AATD neutrophil plasma membranes compared to MM control cells (P<0.0001 and 
P=0.02 respectively, N=3 subjects per group, Student’s t-test). (G) TNF- primed 
MM control neutrophils (5x10
5
) were fMLP (10
-6




generation compared to stimulation by lactoferrin autoantibodies (anti-Lf, 1g). 
Controls for this experiment included cells exposed to TNF- only (10ng) or cells 
exposed to isotype control antibody (1g). (H) A comparison of O2
-
 generated by MM 
and ZZ-AATD cells post 30 min exposure to lactoferrin autoantibodies (anti-Lf, 1g) 
in the presence or absence of TNF- (10ng). Lactoferrin antibodies induced 
significantly more O2
-
 release from ZZ-AATD neutrophils compared to MM cells 
(P=0.004, N=3 subjects per group, Student’s t-test). (I) TNF- (10ng for 10min) 
primed MM control neutrophils (5x10
5
) were stimulated by fMLP (10
-6
M) or purified 
plasma ZZ-AATD lactoferrin autoantibodies (Purified anti-Lf, 300ng) and the rate of 
O2
-
 generation compared at 60 min was not statistically significant (P=0.06, N=3 MM 
subjects, Student’s t-test). Controls included untreated cells or those exposed to either 
TNF- or purified autoantibody only (300ng). O2
-
 is expressed as a % of the response 
to TNF- and fMLP. Each measurement in E, F, H and I are the mean ± SEM from 




































Fig. 5. AAT modulates TNF-α signaling by affecting TNF-, TNF R1 and TNF 
R2 interaction.  
(A) TNF- qRT-PCR results of HL-60 cell RNA post-exposure to TNF-α or TNF-α 
and AAT (27.5μM) for 6 h. TNF-α gene expression was significantly inhibited when 
incubated in the presence of AAT (P=0.03, N=3 independent experiments, Student’s t-
test). (B) Western blot densitometry analysis of HL-60 cells treated for 20 min with 
TNF-α ± AAT (27.5μM) normalized to GAPDH.  Results in arbitrary densitometry 
units (DU) indicate that TNF-α exposure caused decreased levels of I-κBα, indicative 
of NF-κB activation. IκBα degradation was reduced by the addition of AAT (P=0.03, 
N=3 independent experiments, Student’s t-test). (C) Western blot densitometry 
analysis of MM and ZZ-AATD neutrophil whole cell lysates. Significantly reduced 
IκBα levels were detected in the ZZ-AATD samples as compared to healthy MM 
control cells (P=0.04, N=5 subjects per group, Student’s t-test). (D) Biacore analysis 
indicates that AAT does not interact directly with TNF-. An anti-TNF- monoclonal 
antibody was used as a positive control to demonstrate a binding event. Analysis of 
TNF- interaction with immobilised TNF R1 (E) and TNF R2 (F) in the absence or 
presence of AAT or a TNF- blocker. Results indicate that AAT reduced TNF- 
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binding to TNF R1 and R2 by 40 % (P=0.03, N=3 independent experiments, Student’s 
t-test) and 50 % (P=0.02, N=3 independent experiments, Student’s t-test), 
respectively. Similarly the TNF- blocker caused a significant reduction in TNF- 
binding to TNF R1 and R2 (P<0.0001 and P<0.0001, N=3 independent experiments, 
Student’s t-test). (G) Flow cytometry analysis demonstrates that AAT interacts with 
TNF R1 and TNF R2 coated polybeads when compared to beads alone (P=0.01 and 
P=0.04, N=3 independent experiments, Student’s t-test) or FcRIIA coated beads 
(P=0.03 and P=0.02, N=3 independent experiments, Student’s t-test). (H) Analysis of 
the ability of exogenous TNF-to bind to the neutrophil was examined by flow 
cytometry. Cells incubated with AAT (27.5M) and exposed to TNF- displayed a 
significant reduction in the mean fluorescence intensity units (MFI) when compared 
to cells incubated with TNF- only (P<0.0001, N=3 MM subjects, Student’s t-test). 
Each measurement in A-C and H is the mean ± SEM from biological replicates. 








































Fig. 6. Augmentation therapy impacts on neutrophil membrane proteins and 
autoimmunity.  
Neutrophils and plasma were isolated from healthy controls (MM), ZZ-AATD 
patients receiving augmentation therapy for over 4 years (aug ther ZZ) or ZZ-AATD 
patients not receiving augmentation therapy (ZZ). Flow cytometry analysis for 
membrane bound AAT (A) or TNF-B demonstrated that augmentation therapy 
significantly increased membrane AAT yet decreased membrane TNF-levels in ZZ-
AATD patients when compared to patients not receiving therapy (P=0.04 and P=0.01, 
N=3 subjects per group, Student’s t-test). Membrane levels of AAT and TNF-were 
not significantly different between the MM group and ZZ-AATD patients receiving 
therapy (P=0.6 and P=0.8 respectively, N=3 subjects per group, Student’s t-test). 
Results expressed as mean fluorescence intensity (MFI). (C) ZZ-AATD patients 
receiving augmentation therapy demonstrated a significant decrease in soluble plasma 
TNF R1 compared to ZZ-AATD patients not receiving augmentation therapy (P=0.03, 
N=3 subjects per group, Student’s t-test), but similar to levels in MM control plasma 
samples (P=0.1, N=3 subjects per group, Student’s t-test). (D) IgG autoantibodies 
against lactoferrin were quantified in plasma of ZZ-AATD individuals prior to 
receiving augmentation therapy (pre-aug ther) and from the same individuals 4 years 
post treatment (4 y post-aug ther). A significant decrease in the titre of lactoferrin 
autoantibodies was detected in ZZ-AATD patients (P=0.04, N=4 subjects per group, 











Fig. 7. Impact of weekly augmentation therapy infusions on AAT, TNF- and 
plasma granule protein levels. 
(A) Increased plasma levels of AAT on day 2 (○) compared to day 7 post (●) 
augmentation therapy in ZZ-AATD patients (P=0.004, N=4 patients, Student’s t-test). 
Flow cytometry analysis of membrane-bound TNF- (B), or CD66b (C),on isolated 
ZZ-AATD neutrophils on day 2 and 7 post-augmentation therapy. Results in mean 
fluorescence intensity units (MFI) demonstrate significantly reduced levels 2 days 
post-augmentation therapy compared to day 7 (P=0.0004 and P=0.03, N=4 paired 
patient samples, Student’s t-test). (D-F) Levels of active MMP-9 (D; expressed as 
arbitrary densitometry units (DU)), hCAP-18 (E) and lactoferrin (F) were 
significantly lower in plasma of ZZ-AATD individuals on day 2  post infusion 
compared to day 7 post therapy (P=0.01, P=0.03 and  P=0.04 respectively, N=4 
patients, Student’s t-test). Zymography gel in D is 1 of 3 separate experiments. Each 



















Fig. 8. AAT modulates TNF- signaling in neutrophils.  
Physiological serum levels of AAT modulate TNF- signaling (1). In ZZ-AATD, the 
low level of AAT results in increased TNF- signaling (2), neutrophil priming and 
increased degranulation of secondary and tertiary granules (3). The described 
excessive degranulation can lead to development of autoantibodies against released 
granule proteins including lactoferrin (4). These autoantibodies can lead to activation 
of the neutrophil in ZZ-AATD resulting in production of ROS (5). Augmentation 
therapy restores the concentration of AAT in the circulation to normal levels, thereby 
modulating TNF-signaling, preventing neutrophil degranulation and averting an 

















Equal tertiary and secondary granule protein expression in MM and ZZ-AATD 
neutrophils 
 
(A) Western blots of whole cell lysates (WCL) prepared from healthy control (MM) 
and ZZ-AATD (ZZ) neutrophils probed for MMP-9, hCAP-18, lactoferrin and 
GAPDH (loading control). (B) Densitometry values of the expression levels of MMP-
9 (P=0.7, N=5 subjects per group, Student’s t-test), (C) hCAP-18 (P=0.8, N=5 
subjects per group, Student’s t-test) and (D) lactoferrin (P=0.8, N=5 subjects per 
group, Student’s t-test) were not statistically significant between MM and ZZ-AATD. 













TNF- exposure for 20 min does not induce apoptosis in MM or ZZ-AATD 
neutrophils  
(A-D) MM and ZZ-AATD neutrophils incubated with or without TNF- (10ng/2x107 
cells) for 20 min at 37
o
C. Annexin V staining was performed to quantify apoptosis 
and propidium iodide (PI) staining to indicate the number of dead cells (% of 10,000 
cells). Panels (A-D) show representative dot plots of dual annexin V (X-axis) and PI 
(y-axis) staining. (A) demonstrates dual staining of MM unstimulated neutrophils and 
(B) MM cells cultured with  TNF- for 20 min, (C) ZZ-AATD neutrophils 
unstimulated and (D) cultured with  TNF- for 20 min. (E&F) Bar graphs 
demonstrating the percentage of live, apoptopic (early and late) and dead cells (PI) for 
MM ± TNF- (E) and ZZ-AATD ± TNF- (F). Each measurement is the mean ± 






Physiological and acute phase levels of AAT modulates TNF- induced 
degranulation  
 
(A) Expression levels of phospho- MAP kinase p38 post TNF- (2.5ng/1x107 cells) 
treatment in neutrophil lysates were measured by Western blot analysis. AAT 
significantly inhibited MAP kinase p38 activity with an IC50 of 29.15M. AAT levels 
(27.5-110M) significantly reduced p38 phosphorylation (P<0.0001, P<0.0001 and 
P=0.005 for 27.5M, 55M and 110M AAT respectively, N=3 MM subjects, 
Student’s t-test). Western blot analysis and densitometry of degranulated markers 
MMP-9 (B), hCAP-18 (C) and lactoferrin (D) in response to TNF- in the presence 
of increasing concentrations of AAT. Results revealed that physiological levels of 
AAT (27.5M) and up to acute phase levels of AAT (110M) significantly reduced 
neutrophil degranulation (N=3 MM subjects, Student’s t-test). Each measurement is 













IgM autoantibodies against granule proteins in ZZ-AATD. 
IgM autoantibodies against MMP-9 (A), hCAP-18 (B) and lactoferrin (C) were 
quantified in plasma of MM healthy controls and ZZ-AATD individuals. No 
significant difference in IgM titres were observed for MMP-9, hCAP-18 or lactoferrin 
between MM and ZZ (P=0.8, P=0.9 and P=0.8, respectively, N=30 subjects per group, 
Mann-Whitney U test). Positivity was set as 3 standard deviations above the mean of 
MM healthy controls as indicated by the hatched line. Of the ZZ-AATD samples 1/30, 





































Augmentation therapy does not impact upon soluble plasma levels of TNF R2.  
 
Soluble TNF R2 was quantified in plasma from healthy control (MM), ZZ AATD 
(FEV1 30-80%, ZZ) and ZZ-AATD patients receiving augmentation therapy (aug ther 
ZZ) (FEV1 30-80%) by ELISA.  Results demonstrated no significant difference in 
soluble plasma levels of TNF R2 between the three groups (MM versus ZZ or ZZ 
versus aug ther ZZ, P=0.3; MM versus aug ther ZZ, P=0.8. N=3 subjects per group, 































Loading controls for Western blots analysing healthy control (MM) and ZZ-
AATD neutrophil degranulation.  
 
An evaluation of tertiary (MMP-9) and secondary granule (hCAP-18 & Lactoferrin) 
release from unstimulated (A) and TNF- stimulated (B) MM and ZZ-AATD 
neutrophils. The use of equal cell numbers in each reaction is demonstrated by the 
identical electrophoretic profile of whole cell lysates in the Coomassie blue stained 
gels (loading control). The Coomassie gels and corresponding Western blots are 

































Loading controls for Western blots analysing the effect of AAT compared to 
antithrombin III on neutrophil degranulation.  
 
(A) An evaluation of tertiary (MMP-9) and secondary granule (hCAP-18 & 
lactoferrin) release by MM cells treated with TNF- ± AAT or (B) TNF- ± 
antithrombin III (AThrIII). The use of equal cell numbers in each reaction is 
demonstrated by identical electrophoretic profiles of whole cell lysates in the 
Coomassie blue stained gel (loading control).  
(C) Impact of AAT on TNF- induced neutrophil degranulation in ZZ-AATD cells. 
The use of equal cell numbers in each reaction is demonstrated by the identical 
electrophoretic profile of whole cell lysates in the Coomassie blue stained gel (loading 
control).  









Isotype controls for flow cytometry analysis of MM and ZZ-AATD neutrophils 
for TNF-, lactoferrin, AAT and CD66b 
  
(A) Expression levels of TNF- and (B), lactoferrin on MM control (green histogram) 
and non-obstructed ZZ-AATD neutrophils (purple histogram). Relative isotype 
control antibodies, mouse IgG1 (A) and rabbit IgG (B) are illustrated (black filled 
histogram). 
(C) Membrane expression levels of AAT and (D), TNF-, on neutrophils of MM 
controls (yellow histogram), ZZ-AATD patients day 2 post augmentation therapy 
(green histogram) and ZZ-AATD patients who never received augmentation therapy 
(purple histogram). Relative isotype control antibodies, goat IgG (C) and mouse IgG1 
(D) are illustrated (black filled histogram).  
(E) The impact of augmentation therapy on levels of membrane-bound CD66b and 
(F), TNF- on isolated ZZ-AATD neutrophils on day 2 (green histogram) and 7 days 
post-augmentation therapy (purple histogram). Relative isotype control antibodies, 
mouse IgM (E) and mouse IgG1 (F) are represented in each graph (black filled 
histogram). Histograms in A-D are representative of N=3 subjects per group.  







Isotype control for flow cytometry analysis of the ability of AAT to modulate 
neutrophil membrane TNF- interaction. 
 
The ability of exogenous TNF- (10ng/2x10
7
 cells) to bind neutrophil membranes 
was examined by flow cytometry. Cells were untreated (green histogram) or incubated 
with exogenous TNF-  (purple histogram) or TNF- in the presence of physiological 
concentrations of AAT (27.5M) (yellow histogram). Relative mouse IgG isotype 
control antibody (mouse IgG1) is illustrated (black filled histogram). Represented 
result is one of three experiments. 
 
 
 
